

## COVID-19 treatments under evaluation

The **Human Medicines Committee (CHMP)** at **EMA** is evaluating a marketing authorisation application for the following COVID-19 treatments



Treatment	Developer	Description	EMA evaluation process	Start of evaluation	More information
<b>Dexamethasone Taw</b>	Taw Pharma	Dexamethasone medicines have anti-inflammatory properties. Dexamethasone Taw is being developed as a hybrid medicine. It is similar to a 'reference medicine' (i.e. Fortecortin Inject) containing the same active substance, but differs in certain respects, such as strength, use or pharmaceutical form. Dexamethasone Taw will be available as an injectable medicine and, if authorised, will be used to treat the same conditions with the addition of COVID-19	Accelerated assessment	31/08/2020	<a href="https://www.ema.europa.eu/en/news/ema-receives-application-marketing-authorisation-dexamethasone-taw-covid-19">https://www.ema.europa.eu/en/news/ema-receives-application-marketing-authorisation-dexamethasone-taw-covid-19</a>